Ticker brief
HCM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
4
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-07-02 · now +0.49 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 2 | +0.42 |
| @CrweWorld | C | · | 1 | +0.30 |
| @EmmanuelInvest | C | -1.12 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.60 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @BiopharmIQ | +0.50 | Biotech catalyst roundup cites clinical data, approval, FDA news, and financing. | · | tweet ↗ |
| 2026-07-02 | @BiopharmIQ | +0.35 | Biotech midday mover list with catalysts and percentage moves. | · | tweet ↗ |
| 2026-07-02 | @OpenOutcrier | +0.60 | HUTCHMED announces NMPA approval for ORPATHYS in gastric cancer patients. | · | tweet ↗ |
| 2026-07-02 | @EmmanuelInvest | +0.50 | HUTCHMED received NMPA conditional approval for ORPATHYS in gastric cancer. | · | tweet ↗ |
| 2026-06-24 | @CrweWorld | +0.30 | HUTCHMED highlights pivotal Phase II data for Fanregratinib at ESMO GI 2026. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.